Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

InnoCare Approved to Start Trials of JH2 Inhibitor for Autoimmune Diseases

publication date: Mar 28, 2022

Beijing InnoCare Pharma was approved to start China clinical trials of its TYK2 JH2 allosteric inhibitor, the company’s third candidate for autoimmune disease to enter the clinic. ICP-488 binds the JH2 domain to block the signal transduction of IL-23, IL-12, type 1 IFN and other inflammatory cytokines, inhibiting the autoimmune/inflammatory process. InnoCare said the self-developed drug will be tested in patients with psoriasis and inflammatory bowel disease. In 2021, InnoCare out-licensed ex-China rights for its BTK inhibitor to Biogen in a $937 million deal, including $125 million upfront. More details....

Stock Symbols: (HK: 09969) (NSDQ: BIIB)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital